Bernstein cuts Philips stock target to $33, maintains Outperform

Published 23/01/2025, 20:06
Bernstein cuts Philips stock target to $33, maintains Outperform

On Thursday, Bernstein SocGen Group adjusted the price target for Philips Electronics (NYSE:PHG) shares, bringing it down to $33.00 from the previous $36.50, while still maintaining an Outperform rating for the company. According to InvestingPro data, the stock is currently trading near its Fair Value, with analyst targets ranging from $29 to $39. Analyst Lisa Bedell Clive cited Philips as the "Best of Bernstein" pick for the first quarter of 2025, acknowledging that despite a solid year of recovery in 2024, with a 16.9% price return over the past year, the company faced unforeseen challenges in the third quarter, particularly within the Personal Health sector in China.

The adjustment in Philips' price target reflects a revision of forecasts due to the unexpected headwind in China, which impacted consumer spending and, consequently, the company's Personal Health business. Despite current challenges, InvestingPro analysis shows positive indicators, with net income expected to grow this year and two analysts revising their earnings upward for the upcoming period. Clive notes that although the forecasts have been revised downwards, the potential risk-adjusted return remains appealing. InvestingPro subscribers have access to 8 additional key insights about Philips' financial outlook.

Philips is recognized for its strong position in the healthcare industry, aligning with multiple megatrends such as the integration of data analytics and artificial intelligence, along with enhancements in hospital equipment and IT systems aimed at boosting efficiency and workflow. These factors contribute to mid to high single-digit growth in the majority of Philips' end-markets.

The analyst pointed out that while the investment community often regards Philips as a distant third in the Diagnostic Imaging sector, it's important to highlight that 70% of the company's revenues come from business lines where Philips holds either the number one or number two position globally.

The report also addressed the situation in China, stating that while consumer spending has been weak for some time, the significant setback to the Personal Health sector in the third quarter of 2024 came as a surprise. Despite this, the impact of this headwind is believed to be already factored into the company's current valuation.

In other recent news, Royal Philips has been the recipient of a significant investment and has also seen shifts in its financial performance. The U.S. Department of Defense (DoD) has invested $25 million in Philips to enhance the predictive health monitoring of military personnel using the Rapid Analysis of Threat Exposure (RATE) algorithm. This initiative, which will unfold over the next four years, aims to improve the well-being and readiness of active-duty service members by making the technology more accessible in the field.

Additionally, Philips NV has experienced an upgrade from Jefferies, moving its stock rating from Underperform to Hold. This upgrade comes after Philips reported a 2% drop in order intake and revised its sales guidance for fiscal year 2024 downwards. Despite these challenges, Philips has reported stable performance in its third quarter 2024 earnings call, managing to improve profitability amid market challenges, particularly in China.

These recent developments, as well as operational improvements and savings plans, highlight Philips' commitment to navigate market challenges while maintaining a strong focus on profitability and efficiency. Philips anticipates growth in the Connected Care segment by 3%-5% and a slight decline in Personal Health. The company also expects a restructuring charge of EUR 165 million in the fourth quarter, including EUR 100 million related to Connected Care due to asset impairment.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.